Scientific Opinion on the substantiation of health claims related to conjugated linoleic acid (CLA) isomers and contribution to the maintenance or achievement of a normal body weight (ID 686, 726, 1516, 1518, 2892, 3165), increase in lean body mass (ID 498, 731), increase in insulin sensitivity (ID 1517), protection of DNA, proteins and lipids from oxidative damage (ID 564, 1937), and contribution to immune defences by stimulation of production of protective antibodies in response to vaccination (ID 687, 1519) pursuant to Article 13(1) of Regulation (EC) No 1924/2006: EFSA-Q-2008-1285 , EFSA-Q-2008-1351 , EFSA-Q-2008-1473 , EFSA-Q-2008-1474 , EFSA-Q-2008-1513 , EFSA-Q-2008-1518 , EFSA-Q-2008-2253 , EFSA-Q-2008-2254 , EFSA-Q-2008-2255 , EFSA-Q-2008-2256 , EFSA-Q-2008-2670 , EFSA-Q-2008-3625 , EFSA-Q-2008-3897

Inge Tetens

Research output: Book/ReportReportpeer-review

Original languageEnglish
PublisherEuropean Food Safety Authority
Publication statusPublished - 2010

Keywords

  • anti-inflammatory cytokines
  • insulin sensitivity
  • t11 and t10
  • pro-inflammatory
  • immune defences
  • Conjugated linoleic acid (CLA)
  • isomers c9
  • health claims
  • body weight
  • c12
  • lean body mass

Cite this